吉非替尼诊断性治疗肺癌的疗效观察
x

请在关注微信后,向客服人员索取文件

篇名: 吉非替尼诊断性治疗肺癌的疗效观察
TITLE:
摘要: 目的:观察分子靶向药物诊断性治疗肺癌的疗效。方法:选取在我院接受治疗的拟诊肺癌患者120例。所有患者采取常规辅助检查联合吉非替尼250 mg,qd诊断性治疗,4周为1个疗程,共治疗2个疗程。观察所有患者的疗效、症状改善情况、肺癌检出率、症状评分和生存质量评分。结果:所有患者有效率为91.67%,肺癌检出率为48.33%,有效率及检出率均较高;治疗后,所有患者症状评分均低于治疗前,生存质量量表评分优于治疗前,差异有统计学意义(P<0.05)。结论:分子靶向药物诊断性治疗肺癌具有较高的有效率及检出率,有助于改善患者临床症状,提高其生存质量。
ABSTRACT: OBJECTIVE: To observe therapeutic efficacy of diagnostic treatment of molecular targeted drugs for lung cancer. METHODS: 120 cases of suspected lung cancer were selected in our hospital, and were given regular auxiliary examination combined with gefitinib 250 mg,  qd, diagnostic treatment. A treatment course lasted for 4 weeks, and they received 2 courses of treatment. The therapeutic efficacy, symptom improvement, the rate of lung cancer detection, symptom score and quality of life score were observed. RESULTS: The effective rate of all patients was 91.67%, and lung cancer detection rate was 48.33%, two indicators were in high level; after treatment, symptom score of all patients was lower than before, while quality of life score was better than before, with statistical significance  (P<0.05). CONCLUSIONS: The diagnostic treatment of molecular targeted drug for lung cancer has a high effective rate and detection rate, and help to improve clinical symptoms and the quality of life.
期刊: 2016年第27卷第2期
作者: 秦泊洋,韩多林
AUTHORS: QIN Boyang,HAN Duolin
关键字: 吉非替尼;分子靶向药物;诊断性治疗;肺癌;疗效
KEYWORDS: Gefitinib; Molecular targeted drugs; Diagnostic treatment; Lung cancer; Efficacy
阅读数: 381 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!